Literature DB >> 7792559

Ceftriaxone vs cefuroxime for infection prophylaxis in coronary bypass surgery.

T Sisto1, J Laurikka, M R Tarkka.   

Abstract

The most serious infection after coronary artery bypass grafting (CABG) is mediastinitis following deep sternal wound infection. Antibiotic prophylaxis for at least 48 hours has been recommended. In this trial 551 consecutive patients were randomized to receive ceftriaxone in a single dose or cefuroxime thrice daily until the end of the second postoperative day. The overall infection rate was 7.7% in the ceftriaxone and 8.3% in the cefuroxime group, and the incidence of deep sternal infection was 2.9% in both groups. Significant risk factors for such infection were chronic respiratory disease (p < 0.001) and diabetes (p < 0.01). The antibiotic prophylaxis had no harmful effects on the colonic flora in either group. Acquisition and delivery costs for the prophylactic agents were three times higher in the cefuroxime than in the ceftriaxone group. Both antibiotics are concluded to be equally safe and effective. Single-dose ceftriaxone prophylaxis is as effective as cefuroxime given for 48 hours postoperatively. Single-dose ceftriaxone is also simple to use.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7792559     DOI: 10.3109/14017439409099119

Source DB:  PubMed          Journal:  Scand J Thorac Cardiovasc Surg        ISSN: 0036-5580


  3 in total

1.  A meta-analysis of randomized, controlled trials assessing the prophylactic use of ceftriaxone. A study of wound, chest, and urinary infections.

Authors:  J C Woodfield; N Beshay; A M van Rij
Journal:  World J Surg       Date:  2009-12       Impact factor: 3.352

2.  Ceftriaxone versus Other Antibiotics for Surgical Prophylaxis : A Meta-Analysis.

Authors:  Silvano Esposito; Silvana Noviello; Alessandro Vanasia; Paola Venturino
Journal:  Clin Drug Investig       Date:  2004       Impact factor: 2.859

Review 3.  Systematic review of the cost-effectiveness of preoperative antibiotic prophylaxis in reducing surgical-site infection.

Authors:  J Allen; M David; J L Veerman
Journal:  BJS Open       Date:  2018-04-14
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.